How we’re breaking the pattern: our focus on the gut.
Our research focuses on addressing the source of obesity and type 2 diabetes in the body: key metabolic control organs in the gut, specifically in the duodenum and pancreas.
By addressing the organ level root cause of metabolic disease, we believe there is an opportunity to develop transformative therapies that can potentially prevent and eliminate these conditions.
Therapies that target previously unaddressable unmet needs in obesity and type 2 diabetes.
| Obesity | Type 2 Diabetes | |
|---|---|---|
| Revita® | Weight maintenance1 | Prevention3 |
| Rejuva® | Remission2 | Remission4 |
Our presentations, scientific posters, and publications.
- FDA Guidance for Industry Developing Products for Weight Management February 2007.
- Adapted from Hatoum et al JAMA Surgery Feb 2016.
- FDA Draft Guidance: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention February 2008 (withdrawn), Section V.B.5 Prevention of Type 2 Diabetes Mellitus
- Buse et al Diabetes Care. 2009 32:2133-2135.
Revita® is for investigational use only in the US under Federal law. We hereby disclaim any warranties or guarantees regarding the efficacy or safety of Revita®. While we strive for quality and reliability, individual results may vary. Users are encouraged to consult with healthcare professionals and assess personal suitability before using the device.
Rejuva® is in early development and not approved by any regulatory body for investigational or commercial use.